Table 3 Main National Cancer Institute Common Toxicity Criteria adverse events (exposed population)
From: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Number of patients (%) ( n =67) | |||
|---|---|---|---|
Adverse events | All grades 1–4 | Grade 3 | Grade 4 |
Haematological | |||
Anaemia | 52 (77.6) | 5 (7.5) | 2 (3.0) |
Thrombocytopenia | 46 (68.7) | 9 (13.4) | 1 (1.5) |
Neutropenia | 26 (38.8) | 5 (7.5) | 3 (4.5) |
Neutropenic infection | 2 (3.0) | 2 (3.0) | 0 (0.0) |
Febrile neutropenia | 1 (1.5) | 1 (1.5) | 0 (0.0) |
Non-haematological | |||
Alanine aminotransferase increase | 42 (62.7) | 8 (11.9) | 1 (1.5) |
Aspartate aminotransferase increase | 1 (1.5) | 0 (0.0) | 0 (0.0) |
Hyperbilirubinaemia | 3 (4.5) | 3 (4.5) | 0 (0.0) |
Nausea | 55 (82.1) | 3 (4.5) | 0 (0.0) |
Vomiting | 38 (56.7) | 7 (10.4) | 0 (0.0) |
Weight loss | 41 (61.2) | 3 (4.5) | 0 (0.0) |
Fatigue | 49 (73.1) | 4 (6.0) | 3 (4.5) |
Peripheral sensory neuropathy | 45 (67.2) | 4 (6.0) | 0 (0.0) |
Pain | 40 (59.7) | 8 (11.9) | 0 (0.0) |
Infection | 14 (20.9) | 5 (7.5) | 0 (0.0) |
Thrombosis | 3 (4.5) | 2 (3.0) | 1 (1.5) |
